logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2019 — Metastatic castration-resistant prostate cancer: cabazitaxel reduces risk of death by one-third

Cabazitaxel superior to abiraterone, enzalutamide as a third-line treatment.